DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Primary Hypertension

Intervention: Candesartan Cilexeotil 16mg (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Cristina Pentiuc, Study Director, Affiliation: AstraZeneca

Overall contact:
AstraZeneca Romania Medical Department Clinical Study, Information, Phone: +4021 317 60 41, Email: otilia.radu@astrazeneca.com

Summary

The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.

Clinical Details

Official title: Non-Interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or Add-on Therapy.

Study design: Prospective

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- diagnosis of essential hypertension (mild or moderate as defined in European

Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o. d. within last 2 weeks or more, according to Romanian approved Atacand SPC. Written informed consent to allow access and use(analysis) of data collected

Exclusion Criteria:

- Patients not to be included in the programme: patients who have any contraindication

to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC

Locations and Contacts

AstraZeneca Romania Medical Department Clinical Study, Information, Phone: +4021 317 60 41, Email: otilia.radu@astrazeneca.com

Research Site, Bucuresti, Romania; Recruiting

Research Site, Bacau, Romania; Recruiting

Research Site, Braila, Romania; Recruiting

Research Site, Brasov, Romania; Recruiting

Research Site, Cluj, Romania; Recruiting

Research Site, Constanta, Romania; Recruiting

Research Site, Craiova, Romania; Recruiting

Research Site, Galati, Romania; Recruiting

Research Site, Ghiroda, Romania; Recruiting

Research Site, Iasi, Romania; Recruiting

Research Site, Lugoj, Romania; Recruiting

Research Site, Oradea, Romania; Recruiting

Research Site, Pitesti, Romania; Recruiting

Research Site, Ploiesti, Romania; Recruiting

Research Site, Sibiu, Romania; Recruiting

Research Site, Timisoara, Romania; Recruiting

Additional Information

Starting date: September 2007
Last updated: April 14, 2008

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009